Navigation Links
OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer
Date:6/2/2008

PORTLAND, Ore. In a multi-site study, Oregon Health & Science University Cancer Institute researchers have found that a drug called Ipilimumab, also known as MDX-010, works to stimulate the body's own immune system to fight prostate cancer. The drug was found to be effective in study participants with a serious type of prostate cancer one where the tumor has spread and was resistant to hormonal treatment and, in some cases, also to chemotherapy.

Darryl Pape was one of 19 participants in the Oregon Health & Science University Cancer Institute trial.

"I was in such bad shape. I couldn't even sit on a plane for more than two hours without a lot of pain. I was praying for some clinical trial that would help," said Pape, 54, of Portland, Ore.

Pape was running out of options for his prostate cancer. He was diagnosed almost seven years ago and had tried different cancer drugs, but each only for a while. Last year his cancer count, or prostate specific antigen (PSA), was at a high level -- an indicator that his cancer was growing and spreading and it was not responding to any drugs.

A prostate-specific antigen test measures the amount of prostate-specific antigen in the blood. PSA is released into a man's blood by his prostate gland. Healthy men have low amounts of PSA in the blood. PSA may increase as a result of prostate cancer.

Pape, a very religious man, was looking for a miracle. He found one when he was eligible for a clinical trial testing the effectiveness of Ipilimumab, at the OHSU Cancer Institute. After the first infusion of the drug, Pape said he could feel it working. After the second infusion, he said his symptoms went away.

"I felt great at that point," he said.

Not everyone has the same response, and Pape did suffer some side effects. But one year later, Pape is in complete remission.

"I got my life back," he said.

Tomasz Beer, M.D., a member of the OHSU Cancer Institute, will be giving the oral presentation on this research Monday, June 2, at 11:30 a.m. during the annual American Society of Clinical Oncology in Chicago.

"From what we have seen, this shows that the immune system can be useful to treat prostate cancer. Results show that in some patients, the immune system can be successfully harnessed to cause cancer regressions, and that is both exciting and encouraging," said Beer, the Grover C. Bagby Endowed Chair for Cancer Research, director of the Prostate Cancer Research Program at the OHSU Cancer Institute, associate professor of medicine (hematology/medical oncology), OHSU School of Medicine.

It was confirmed that seven or 21 percent, of the 33 study participants had PSA declines of 50 percent.

The secret to how the drug works lies in a complex set of interactions in the immune system. The immune system is designed to attack foreign invaders such as viruses and bacteria, sending out a barrage of T-cells to destroy it through inflammation or direct killing. The immune system is also thought to play a role in surveillance for the detection and elimination of altered cells of the body, such as cancer cells. Whether a cancer progresses or not depends, in part, on the ability of the cancer to evade the immune response. One way in which cancer cells can evade the immune system is to take advantage of natural controls of the immune response that act to dial down, or down regulate, the strength of the response and allow the tumor to grow.

Scientists have discovered that an important mechanism for down regulation is mediated by a molecule called CTLA-4. The T cells are initially activated by other immune cells, called dendritic cells, that display the foreign, or cancerous, antigens to the T cells and instruct them to be active. After this initial activation, CTLA-4 appears on the surface of the T cells, and when CTLA-4 interacts with the dendritic cells, the next set of signals are to turn the response down, or even off. CTLA-4 is part of a regulatory mechanism that normally protects the body from immune overreactions, but when it is expressed in the presence of mutant cancer cells the result is tumor evasion of the immune response. Ipilimumab is an antibody that blocks CTLA-4, releasing this safety brake, and allowing the immune response to have a stronger anti-tumor effect.


'/>"/>

Contact: Christine Decker
deckerch@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Eva Longoria Parker Participates in 5k Run/Walk to Raise Money for Children With Cancer and Offers Support to Univision Talent Fernando Del Rincons Cancer Diagnosis
2. One A Day(R) and Major League Baseball Raise Over $106,000 to Strike Out Prostate Cancer
3. Vaccine May Boost Survival of Brain Cancer Patients
4. Blocking signaling protein prevents prostate cancer spread, Jefferson scientists find
5. New treatment combination safe for pancreatic cancer patients
6. 3-Drug Combo Improves Advanced Pancreatic Cancer Outcomes
7. U.S. Childhood Cancers Vary by Sex, Region
8. Erbitux Works Well for Two-Thirds of Colon Cancer Patients
9. Anemia Drugs May Speed Tumor Growth in Some Cancer Patients
10. Celebrex May Reduce Levels of Lung Cancer Biomarker
11. Young Hodgkin Survivors Face Later Risk of Second Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
Breaking Medicine Technology: